Efficacy/Safety Study of Nebulized IVX-0142, a Novel Antiallergic Drug, in Mild Allergic Asthma
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
This study is designed to evaluate the effectiveness of nebulized IVX-0142, a novel anti-allergic drug, to inhibit allergen-induced airway narrowing in patients with allergic asthma and the related increased sensitivity of the airways to other substances, as well as to investigate a possible anti-inflammatory effect of the drug in the airways.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years to 60 Years (Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Mild stable allergic asthma
Positive skin-prick test to at least one common aeroallergen
Positive methacholine challenge
Positive allergen-induced early- and late-phase airway bronchoconstriction
General good health
Lung diseases other than mild allergic asthma
History or symptoms of cardiovascular disease, significant neurologic disease, and/or clinically significant autoimmune disease
Chronic use of asthma medications other than short or intermediate beta-agonists or ipratropium
Use of tobacco products within one year starting study or smoking history >10 pack years
If female, pregnant or lactating or have positive pregnancy test at screening